| __timestamp | Amphastar Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 612613000000 |
| Thursday, January 1, 2015 | 46974000 | 650773000000 |
| Friday, January 1, 2016 | 47298000 | 619061000000 |
| Sunday, January 1, 2017 | 50918000 | 628106000000 |
| Monday, January 1, 2018 | 58044000 | 717599000000 |
| Tuesday, January 1, 2019 | 63109000 | 964737000000 |
| Wednesday, January 1, 2020 | 65157000 | 875663000000 |
| Friday, January 1, 2021 | 68920000 | 886361000000 |
| Saturday, January 1, 2022 | 66592000 | 997309000000 |
| Sunday, January 1, 2023 | 80393000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Data in motion
In the ever-evolving pharmaceutical industry, operational costs play a pivotal role in shaping a company's financial health. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry players: Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc., from 2014 to 2023.
Takeda, a global leader, has seen its SG&A expenses soar by approximately 72% over the decade, peaking at over 1 trillion yen in 2023. This growth reflects Takeda's aggressive expansion and strategic acquisitions, positioning it as a formidable force in the pharmaceutical landscape.
In contrast, Amphastar's SG&A expenses have grown by about 99%, reaching nearly 80 million dollars in 2023. This steady increase underscores Amphastar's commitment to innovation and market penetration.
While the data for 2024 is incomplete, the trends from the past decade provide a compelling narrative of strategic financial management in the pharmaceutical sector.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.